August 15, 2011
UrgentÂ® PC Clinical Studies Results Scheduled for Presentation at International Continence Society
MINNETONKA, Minn., Aug. 15, 2011 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of two clinical studies using Uroplasty's UrgentÃ® PC Neuromodulation System are scheduled to be presented at the International Continence Society meeting, August 29-September 2, 2011 in Glasgow, Scotland.
"These data from on-going clinical studies continue to demonstrate the long-term efficacy of percutaneous tibial nerve stimulation (PTNS) delivered via Urgent PC in the treatment of overactive bladder syndrome," said David Kaysen, President and CEO of Uroplasty. "The studies build on a growing body of evidence that validates the treatment protocol, usefulness with both young and elderly patients, and the durability of the improvements with continued PTNS therapy."
SUmiT Trial Outcomes: Clinical Insights into Percutaneous Tibial Nerve Stimulation, presented by Dr. Peter Sand, NorthShore University Health, Chicago, IL
- Demonstrated that results are consistent for patients regardless of age
- Demonstrated that improvement occurs throughout the series of 12 initial treatments, with more improvement occurring during treatments 7 through 12
Treatment Interval Frequency of Percutaneous Tibial Nerve Stimulation: 18-Month Results from the STEP Study, presented by Dr. Kenneth Peters, William Beaumont Hospital, Royal Oak, MI
- Responders to the initial series of 12 treatments treated with regular PTNS therapy, on an average of once per month, sustained their improvements in voiding symptoms and Quality of Life measures throughout 18 months of therapy
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our UrgentÃ® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer MacroplastiqueÃ® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
This press release contains forward-looking statements that reflect our best estimates regarding future events that could affect our financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report and on Form 10-K filed with the SEC. We cannot be certain that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.
Investor Relations Company Contact: Contacts: Media Contact: Uroplasty, Inc. EVC Group, Inc. EVC Group, Inc. Doug Sherk/Jenifer Chris Gale/ Steve David Kaysen, CEO Kirtland DiMattia (952) 426-6140 (415) 568-9349 (646) 201-5431 [email protected] [email protected] [email protected] [email protected] [email protected]
SOURCE Uroplasty, Inc.